SecBot SecBot
SECBOTREPLAY Home › Report › AXSM

AXSM · Axsome reported Q1 2026 revenue of $191.2M (57% YoY growth, slight beat…

Axsome Therapeutics, Inc. · PRESS-RELEASE filed May 4, 2026 at 07:00 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed May 4, 2026 at 07:00 ET

Axsome reported Q1 2026 revenue of $191.2M (57% YoY growth, slight beat vs $190.7M consensus), but GAAP EPS of -$1.26 missed the -$0.86 consensus by 46.5% due to higher SG&A and R&D costs. The recent FDA approval of Auvelity for Alzheimer's agitation is a key catalyst, but widening losses and rising expenses temper optimism.

  • Q1 2026 net product revenue $191.2M, +57% YoY vs $121.5M
  • AUVELITY revenue $153.2M, +59% YoY; ~223,000 prescriptions written
  • SUNOSI revenue $33.9M, +34% YoY; SYMBRAVO revenue $4.1M
  • GAAP net loss $(64.5M) or $(1.26)/share vs $(59.4M) or $(1.22)/share in Q1 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access